Compare Abeona Therapeutics Inc (ABEO) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Sezzle Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Sezzle Inc trades at $126 (market cap $4.32B). The key difference: Sezzle Inc is far larger — about 10.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SEZL | |
|---|---|---|
Market Cap | $421.19M | $4.32B |
Sector | Health | Technology |
52-Week High | $7.45 | $188.55 |
52-Week Low | $4.17 | $50.97 |
Enterprise Value | $276.10M | $4.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Sezzle (SEZL) trades at $125.44, up 6.31% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 30.35% net income margin and consistent earnings beats. Recent Q2 2026 results showed revenue growth of 51.7% year-over-year to $149.7 million, with management raising full-year guidance for the third time in 2026, indicating robust operational momentum despite a recent stock decline.
The outlook is mixed: bullish fundamentals and analyst consensus support upside to a $158.29 price target, but technical indicators and valuation premiums pose risks. Key opportunities include subscriber growth and AI integration, while risks involve execution pressure and market volatility. Investors should weigh strong profitability against high P/E and P/S ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
